Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
about
MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell linesMelatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism.Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatmentPhosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.Tamoxifen Action in ER-Negative Breast Cancer.Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.MARCKS protein overexpression in inflammatory breast cancer.PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells.Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.50 years of The FEBS Journal: looking back as well as ahead.Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers.Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
P2860
Q33597596-14F606FC-930B-4092-A803-BDB8A84D7EF1Q33624824-8BCAE32E-C58A-47B3-B946-A064C9C761F8Q33992390-34F37D92-5732-4D04-8C99-3D169E789397Q35830288-C0ECB77F-812A-4CD8-83DC-2D892FE6F16BQ36020972-B66B0AAA-F125-4C52-99A8-759317CAD6C9Q36263003-8DEF5A8D-7CD1-4754-87E5-1864F1719E62Q36688302-93B28587-0095-4A0F-AE81-EA27BD9A6EB3Q37362627-10DCAF6A-86E2-4045-A54F-A68D9865EDD9Q37698720-9B788A69-60C0-45F3-81F6-8E9676AECB7DQ37701585-33E0E3A2-446F-46AB-9BD6-738903016C46Q38794535-87BFB7BF-EB76-4B28-B4F1-95AD485B57E1Q38976447-65BA353D-90C9-4D9A-ACC4-6B2B058590D5Q47181311-48DB5794-3520-4C1B-9EE8-927FA9B0B969Q47547794-5C1E132D-5A06-4A74-ADC6-020C8403C701Q47642445-56FD1118-2894-4638-8930-E02B231E9BF9Q53763092-33FA9809-B37F-485C-BAE6-C255D5223A2C
P2860
Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Global characterization of sig ...... n resistance in breast cancer.
@ast
Global characterization of sig ...... n resistance in breast cancer.
@en
Global characterization of sig ...... n resistance in breast cancer.
@nl
type
label
Global characterization of sig ...... n resistance in breast cancer.
@ast
Global characterization of sig ...... n resistance in breast cancer.
@en
Global characterization of sig ...... n resistance in breast cancer.
@nl
prefLabel
Global characterization of sig ...... n resistance in breast cancer.
@ast
Global characterization of sig ...... n resistance in breast cancer.
@en
Global characterization of sig ...... n resistance in breast cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Global characterization of sig ...... en resistance in breast cancer
@en
P2093
Alice Boulghourjian
Andrew Stone
Brigid C Browne
Caroline Roberts
Christine S Lee
Elizabeth A Musgrove
Falko Hochgräfe
Jane Barraclough
Jianmin Wu
Lynn Farrow
P2860
P304
P356
10.1111/FEBS.12441
P407
P577
2013-08-19T00:00:00Z